|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||0.00 / 0.00|
Results Confirm Clinical Activity of the Novel Hypomethylating Agent SGI-110 in Intermediate or High Risk MDS Patients Previously Treated With Azacitidine or Decitabine
Investors eyeing a purchase of Astex Pharmaceuticals Inc stock, but cautious about paying the going market price of $4.57/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2014 put at the $3.50 strike, which has a bid at the time of this writing of 55 cents.
The most recent short interest data has been released by the NASDAQ for the 04/30/2013 settlement date, which shows a 804,039 share increase in total short interest for Astex Pharmaceuticals Inc , to 5,839,281, an increase of 15.97% since 04/15/2013. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
Strategies that follow hard rules usually don't work. But some, it turns out, are legit.
TheStreet Ratings released rating changes on 80 U.S. common stocks for week ending March 1, 2013. 56 stocks were upgraded and 24 stocks were downgraded by our stock model.
Traders savvy enough to follow the low-priced names and trade them with discipline and sound risk management are banking ridiculous coin on a regular basis.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.